News | April 14, 2024
Briefs: Sun Pharma and Kimia Biosciences
Sun Pharma's Dadra facility receives OAI status from US FDA
Sun Pharma's Dadra facility receives OAI status from US FDA
Decision on EU marketing authorisation expected for momelotinib by early 2024
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
AAT is a substantial socio-economic burden to livestock farmers in Sub-Saharan Africa, affecting and killing millions of cattle every year
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
Launches Thalassemia Bal Sewa Yojana portal and releases standard treatment guidelines for sickle cell anemia disease
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)